Millipore Sigma Vibrant Logo

MAB1680 Anti-Filamin A Antibody, clone TI10

View Products on Sigmaaldrich.com
MAB1680
100 µL  
Retrieving price...
Price could not be retrieved
Minimum Quantity is a multiple of
Maximum Quantity is
Upon Order Completion More Information
You Saved ()
 
Request Pricing
Limited Availability
Limited Availability
In Stock 
Discontinued
Limited Quantities Available
Availability to be confirmed
    Remaining : Will advise
      Remaining : Will advise
      Will advise
      Contact Customer Service
      Contact Customer Service

      Special Offers

       

      Contact Customer Service

      Overview

      Replacement Information

      Key Spec Table

      Species ReactivityKey ApplicationsHostFormatAntibody Type
      B, HIP, WB, IHC, IH(P)MAscitesMonoclonal Antibody
      Description
      Catalogue NumberMAB1680
      ReplacesCBL229
      Brand Family Chemicon®
      Trade Name
      • Chemicon
      DescriptionAnti-Filamin A Antibody, clone TI10
      Alternate Names
      • Alpha-Filamin
      • Filamin I
      • Endothelial Actin-binding Protein
      • ABP-280
      • Nonmuscle Filamin
      Background InformationFilamin is a structural protein that forms flexible cross-links between two actin filaments. Filamin is a homodimer of polypeptide chains each joined to the other at one end with an actin binding site ath the other. It is present in smooth muscle, fibroblasts, platelets and lymphocytes.
      References
      Product Information
      FormatAscites
      Control
      • Positive control tisse: skin.
      PresentationAscites. Liquid
      Quality LevelMQ100
      Applications
      ApplicationDetect Filamin A using this Anti-Filamin A Antibody, clone TI10 validated for use in IP, WB, IH, IH(P).
      Key Applications
      • Immunoprecipitation
      • Western Blotting
      • Immunohistochemistry
      • Immunohistochemistry (Paraffin)
      Application NotesImmunoblotting: 1:250 to 1:1000

      Immunoprecipitation:Suggested lysis buffer is PBS with 0.5% triton X-100 with proteinase inhibitors (note for full length filamin include calpain inhibitors). 5 microliters of antibody for every 300μL of cell lysate (3-5mg/ml total protein is suggested). Incubation is 4 hours RT or overnight 4C; Protein A/G agarose beads or rabbit anti-mouse secondary capture antibody is recommended for best recovery. 4-10% acrylamide gels are recommended for full length filamin or the 80kDa fragement visualization.

      Immunofluorescence: 1:50 to 1:200 using standard ABC technique. Suitable for staining of paraffin embedded sections (lower dilutions). High temperature citrate buffer antigen retrieval technique recommended.

      Optimal working dilutions must be determined by end user.
      Biological Information
      ImmunogenHuman platelet protein
      CloneTI10
      HostMouse
      SpecificityHuman filamin (actin-bidning protein). Recognizes unprocessed (270-280 kDa) and the C-terminal 90 kDa calpain cleavage fragment of filamin (Aakhus, 1992).
      IsotypeIgG1
      Species Reactivity
      • Bovine
      • Human
      Antibody TypeMonoclonal Antibody
      Entrez Gene Number
      Entrez Gene SummaryActin-binding protein, or filamin, is a 280-kD protein that crosslinks actin filaments into orthogonal networks in cortical cytoplasm and participates in the anchoring of membrane proteins for the actin cytoskeleton. Remodeling of the cytoskeleton is central to the modulation of cell shape and migration. Filamin A, encoded by the FLNA gene, is a widely expressed protein that regulates reorganization of the actin cytoskeleton by interacting with integrins, transmembrane receptor complexes, and second messengers.[supplied by OMIM]
      Gene Symbol
      • FLNA
      • Alpha-filamin
      • OPD2
      • Filamin-A
      • MNS
      • FLN
      • FMD
      • OPD1
      • FLN1
      • NHBP
      • ABP-280
      • ABPX
      • OPD
      • Filamin-1
      • DKFZp434P031
      Non-Reactive Species
      • Mouse
      • Rat
      UniProt Number
      UniProt SummaryFUNCTION: SwissProt: P21333 # Promotes orthogonal branching of actin filaments and links actin filaments to membrane glycoproteins. Anchors various transmembrane proteins to the actin cytoskeleton and serves as a scaffold for a wide range of cytoplasmic signaling proteins. Interaction with FLNA may allow neuroblast migration from the ventricular zone into the cortical plate. Tethers cell surface- localized furin, modulates its rate of internalization and directs its intracellular trafficking (By similarity).
      SIZE: 2647 amino acids; 280739 Da
      SUBUNIT: Interacts with PDLIM2 (By similarity). Homodimer. Interacts with FLNB, FURIN, HSPB7, INPPL1, KCND2, MYOT, MYOZ1, ARHGAP24, PSEN1 and PSEN2. Interacts also with various other binding partners in addition to filamentous actin.
      SUBCELLULAR LOCATION: Cytoplasm, cell cortex.
      TISSUE SPECIFICITY: Ubiquitous.
      DOMAIN: SwissProt: P21333 Comprised of a NH2-terminal actin-binding domain, 24 internally homologous repeats and two hinge regions. Repeat 24 and the second hinge domain are important for dimer formation.
      PTM: Phosphorylated upon DNA damage, probably by ATM or ATR (By similarity). Phosphorylation extent changes in response to cell activation. & The N-terminus is blocked.
      DISEASE: SwissProt: P21333 # Defects in FLNA are the cause of periventricular nodular heterotopia 1 (PVNH1) [MIM:300049]; also called nodular heterotopia, bilateral periventricular (NHBP or BPNH). PVNH1 is an X-linked developmental dominant disorder in which many neurons fail to migrate into the cerebral cortex. They remain as nodules lining the ventricular surface. In heterozygous females these neurons presumably represent those cells that, after X-chromosome inactivation, contain the active X chromosome with the filamin mutation. Most hemizygous affected males die early during embryogenesis, whereas heterozygous females have normal intelligence but suffer from seizures and various manifestations outside the central nervous system, especially related to the vascular system. This implies that essential embryonic cell migration can only occur in FLNA-expressing cells. & Defects in FLNA are the cause of periventricular nodular heterotopia 4 (PVNH4) [MIM:300537]; also known as periventricular heterotopia Ehlers-Danlos variant. PVNH4 is characterized by nodular brain heterotopia, joint hypermobility and development of aortic dilatation in early adulthood. & Defects in FLNA are the cause of otopalatodigital syndrome type 1 (OPD1) [MIM:311300]. OPD1 is an X-linked dominant multiple congenital anomalies disease mainly characterized by a generalized skeletal dysplasia, mild mental retardation, hearing loss, cleft palate, and typical facial anomalies. OPD1 belongs to a group of X-linked skeletal dysplasias known as oto-palato- digital syndrome spectrum disorders that also include OPD2, Melnick-Needles syndrome (MNS), and frontometaphyseal dysplasia (FMD). Remodeling of the cytoskeleton is central to the modulation of cell shape and migration. FLNA is a widely expressed protein that regulates re-organization of the actin cytoskeleton by interacting with integrins, transmembrane receptor complexes and second messengers. Males with OPD1 have cleft palate, malformations of the ossicles causing deafness and milder bone and limb defects than those associated with OPD2. Obligate female carriers of mutations causing both OPD1 and OPD2 have variable (often milder) expression of a similar phenotypic spectrum. & Defects in FLNA are the cause of otopalatodigital syndrome type 2 (OPD2) [MIM:304120]; also known as cranioorodigital syndrome. OPD2 is a congenital bone disorder that is characterized by abnormally modeled, bowed bones, small or absent first digits and, more variably, cleft palate, posterior fossa brain anomalies, omphalocele and cardiac defects. & Defects in FLNA are the cause of frontometaphyseal dysplasia (FMD) [MIM:305620]. FMD is a congenital bone disease characterized by supraorbital hyperostosis, deafness and digital anomalies. & Defects in FLNA are the cause of Melnick-Needles syndrome (MNS) [MIM:309350]. MNS is a severe congenital bone disorder characterized by typical facies (exophthalmos, full cheeks, micrognathia and malalignment of teeth), flaring of the metaphyses of long bones, s-like curvature of bones of legs, irregular constrictions in the ribs, and sclerosis of base of skull. & Defects in FLNA are associated with cerebrofrontofacial syndrome [MIM:608578]. This syndrome consists of a phenotype of male PVNH, with relatively normal development, no epilepsy or other neurological abnormality, severe constipation, and facial dysmorphism and without a discernible skeletal phenotype. & Defects in FLNA are a cause of X-linked congenital idiopathic intestinal pseudoobstruction (CIIPX) [MIM:300048]. CIIPX is caused by severe abnormality of gastrointestinal motility either due to primary qualitative defects of enteric ganglia and nerve fibers, or secondary to a variety of conditions, such as myopathies, inflammatory or autoimmune diseases, drug toxicity, ischemia, or viral infections. CIIPX is diagnosed by radiological, surgical, or manometric evidence of abnormal bowel motility causing intestinal obstruction in the absence of any mechanical occlusion.
      SIMILARITY: Belongs to the filamin family. & Contains 1 actin-binding domain. & Contains 2 CH (calponin-homology) domains. & Contains 24 filamin repeats.
      Physicochemical Information
      Dimensions
      Materials Information
      Toxicological Information
      Safety Information according to GHS
      Safety Information
      Product Usage Statements
      Usage Statement
      • Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.
      Storage and Shipping Information
      Storage ConditionsMaintain frozen at -20°C for up to 12 months in undiluted aliquots. Avoid repeated freeze/thaw cycles.
      Packaging Information
      Material Size100 µL
      Transport Information
      Supplemental Information
      Specifications
      Global Trade Item Number
      Catalogue Number GTIN
      MAB1680 04053252315312

      Documentation

      Anti-Filamin A Antibody, clone TI10 SDS

      Title

      Safety Data Sheet (SDS) 

      Anti-Filamin A Antibody, clone TI10 Certificates of Analysis

      TitleLot Number
      MOUSE ANTI-HUMAN FILAMIN A 2475756
      MOUSE ANTI-HUMAN FILAMIN A - 2512475 2512475
      MOUSE ANTI-HUMAN FILAMIN A - 3189227 3189227
      MOUSE ANTI-HUMAN FILAMIN A - 3772447 3772447
      MOUSE ANTI-HUMAN FILAMIN A -2616153 2616153
      MOUSE ANTI-HUMAN FILAMIN A -2733757 2733757
      MOUSE ANTI-HUMAN FILAMIN A MONOCLONAL ANTIBODY 2945591
      MOUSE ANTI-HUMAN FILAMIN A MONOCLONAL ANTIBODY 3027061
      MOUSE ANTI-HUMAN FILAMIN A MONOCLONAL ANTIBODY 2880971
      MOUSE ANTI-HUMAN FILAMIN A MONOCLONAL ANTIBODY - 2041567 2041567

      References

      Reference overviewPub Med ID
      Enhancing the effectiveness of androgen deprivation in prostate cancer by inducing Filamin A nuclear localization.
      Mooso, Benjamin A, et al.
      Endocr. Relat. Cancer, 19: 759-77 (2012)  2012

      Show Abstract
      22993077 22993077
      Terminal osseous dysplasia is caused by a single recurrent mutation in the FLNA gene.
      Sun, Y; Almomani, R; Aten, E; Celli, J; van der Heijden, J; Venselaar, H; Robertson, SP; Baroncini, A; Franco, B; Basel-Vanagaite, L; Horii, E; Drut, R; Ariyurek, Y; den Dunnen, JT; Breuning, MH
      American journal of human genetics  87  146-53  2010

      Show Abstract
      20598277 20598277
      Filamin associates with stress signalling kinases MKK7 and MKK4 and regulates JNK activation.
      Kentaro Nakagawa,Misato Sugahara,Tokiwa Yamasaki,Hiroaki Kajiho,Shinya Takahashi,Jun Hirayama,Yasuhiro Minami,Yasutaka Ohta,Toshio Watanabe,Yutaka Hata,Toshiaki Katada,Hiroshi Nishina
      The Biochemical journal  427  2010

      Show Abstract
      20156194 20156194
      Nuclear versus cytoplasmic localization of filamin A in prostate cancer: immunohistochemical correlation with metastases.
      Bedolla, RG; Wang, Y; Asuncion, A; Chamie, K; Siddiqui, S; Mudryj, MM; Prihoda, TJ; Siddiqui, J; Chinnaiyan, AM; Mehra, R; de Vere White, RW; Ghosh, PM
      Clinical cancer research : an official journal of the American Association for Cancer Research  15  788-96  2009

      Show Abstract Full Text Article
      19188148 19188148
      Enhanced interferon signaling pathway in oral cancer revealed by quantitative proteome analysis of microdissected specimens using 16O/18O labeling and integrated two-dimensional LC-ESI-MALDI tandem MS.
      Chi, LM; Lee, CW; Chang, KP; Hao, SP; Lee, HM; Liang, Y; Hsueh, C; Yu, CJ; Lee, IN; Chang, YJ; Lee, SY; Yeh, YM; Chang, YS; Chien, KY; Yu, JS
      Molecular & cellular proteomics : MCP  8  1453-74  2009

      Show Abstract
      19297561 19297561
      Filamin A stabilizes Fc gamma RI surface expression and prevents its lysosomal routing.
      Jeffrey M Beekman,Cees E van der Poel,Joke A van der Linden,Debbie L C van den Berg,Peter V E van den Berghe,Jan G J van de Winkel,Jeanette H W Leusen
      Journal of immunology (Baltimore, Md. : 1950)  180  2008

      Show Abstract
      18322202 18322202
      Structure of three tandem filamin domains reveals auto-inhibition of ligand binding.
      Yatish Lad,Tiila Kiema,Pengju Jiang,Olli T Pentikäinen,Charlotte H Coles,Iain D Campbell,David A Calderwood,Jari Ylänne
      The EMBO journal  26  2007

      Show Abstract Full Text Article
      17690686 17690686
      Rab6 mediates membrane organization and determinant localization during Drosophila oogenesis.
      Jean-Baptiste Coutelis,Anne Ephrussi
      Development (Cambridge, England)  134  2007

      Show Abstract
      17329360 17329360
      Clinical and morphological phenotype of the filamin myopathy: a study of 31 German patients.
      Kley, RA; Hellenbroich, Y; van der Ven, PF; Fürst, DO; Huebner, A; Bruchertseifer, V; Peters, SA; Heyer, CM; Kirschner, J; Schröder, R; Fischer, D; Müller, K; Tolksdorf, K; Eger, K; Germing, A; Brodherr, T; Reum, C; Walter, MC; Lochmüller, H; Ketelsen, UP; Vorgerd, M
      Brain : a journal of neurology  130  3250-64  2007

      Show Abstract
      18055494 18055494
      Expression of ral GTPases, their effectors, and activators in human bladder cancer.
      Smith, SC; Oxford, G; Baras, AS; Owens, C; Havaleshko, D; Brautigan, DL; Safo, MK; Theodorescu, D
      Clinical cancer research : an official journal of the American Association for Cancer Research  13  3803-13  2007

      Show Abstract
      17606711 17606711